Cutting Edge Information Warns of Risks of Anti-Innovation Forces Infiltrating European Commission: EU Witch Hunt

RESEARCH TRIANGLE PARK, NC, Jan 12 (MARKET WIRE) --
A recent European Commission report chastised the pharmaceutical industry
for what it claims are anti-competitive practices aimed to prevent
generic drug manufacturers from entering the market with low-priced
copies of branded prescription medications. In the report, the Commission
claims that big pharma's counter-generics strategies cost European Union
member states around 3 billion euros from 2000 through 2007.

The European Commission's report, which attacks the pharmaceutical
industry for exercising its right to defend its patents and to earn a
return on the billions it invests in research and development, reflects
the Commission's shortsighted vantage point. The Commission conveniently
ignores the billions of euros of value that the pharmaceutical industry
invests in the economy, as well as the immeasurable value that the
industry's R&D innovation generates in quality-of-life improvements and
overall health improvement of the EU member nations.

According to a report, "Combating Generics 2008: Counter-Generics
Strategy, Tactics and Execution" (http://www.PharmaGenerics.com), from
pharmaceutical business intelligence leader Cutting Edge Information,
when regulatory authorities like the European Commission begin to erode
the economic incentives that drive investment in innovation and new drug
discovery and development, they put at risk the lives and well-being of
the very populations they are charged with protecting.

"This European Commission report reveals that the Commission simply does
not understand the full economic and healthcare implications of its policy
stance," says Adam Bianchi, chief operating officer of Cutting Edge
Information. "Ethical drug manufacturers should have every right to file
patent infringement lawsuits to defend their intellectual property,
release new and improved medications designed to replace existing
therapies, and to protect the billions they have invested to bring new
medicines to market."

Cutting Edge Information's report, "Combating Generics 2008:
Counter-Generics Strategy, Tactics and Execution," details the present and
planned future usage of a dozen counter-generics strategies and examines
other counter-generics activity at more than 30 different companies. Data
details investment levels, planning and implementation timelines and the
prominence of different tools and tactics in the fight against generic
competition. The report's findings also explore case studies and the
experiences of real-world brand teams.

A complimentary brochure of "Combating Generics 2008: Counter-Generics
Strategy, Tactics and Execution" is available at
http://www.PharmaGenerics.com.

CONTACT INFORMATION:
Adam Bianchi
Email Contact
919-403-6583

Copyright 2009, Market Wire, All rights reserved.

-0-